Corona Remedies IPO: GMP ahead of listing signals strong debut for shares — Details here

Key Highlights

• As of Sunday, 14 December 2025, the grey market premium (GMP) of the Corona Remedies IPO stands at ₹295 per share.
• With the upper price band of the public issue at ₹1,062, the company's shares are expected to be listed at ₹1,357 apiece, marking a potential listing premium of 28%, according to IPO India data.
• Grey market premium (GMP) is an indicator which shows the investors' willingness to invest in a primary issue.
• Shivani Nyati, Head of Wealth at Swastika Investmart Ltd, expects that the Corona Remedies IPO is set to witness a healthy listing premium of 25% to 27%, with an expected listing price of around ₹1,330-1,350 per share.
• According to the data collected from the BSE website, the Corona Remedies IPO received heavy subscription after its three-day bidding round, as investors booked 137.04 times or 62,65,41,440 shares out of the total 45,71,882 shares on offer.